ABOUT MiNA

Harnessing the innate mechanism of gene activation, MiNA Therapeutics’ platform enables the development of new medicines that restore normal function to patients’ cells. We are applying our technology and clinical know-how to transform the therapy landscape of severe liver and other diseases.

PIONEERING NEW CLASS OF MEDICINES

Small activating RNAs are an entirely new class of medicines with potential to offer transformational benefits to patients across a wide range of diseases.

CLINICAL STAGE PLATFORM

We have developed a systematic approach to take new saRNA medicines from an idea to patients in a clinical trial in just 2 years.

EXPERIENCED TEAM

Driving our platform are a group of passionate scientists, drug developers, doctors and entrepreneurs shaped by experience in oligonucleotide therapeutics, cancer and liver diseases.

TWITTER FEED

Follow us on Twitter

Prof Habib and Dr Sodergren presenting in the afternoon poster session #AACR2019

Poster 3586 | 1pm on Tue Apr 2 | Experimental and Molecular Therapeutics – Novel Antitumour Agents 2 | MTL-CEBPA, a drug candidate for hepatocellular carcinoma enhances efficacy of sorafenib #AACR2019

Poster 3211 | 8am on Tue Apr 2 | Immunology – Combination Immunotherapies 2 | MTL-CEBPA combined with radiofrequency ablation and immunotherapy enhances immunological anti-tumour responses in an HCC mouse model #AACR2019

We're excited to present 2 posters today at #AACR209 showing immunological and anti-tumour effects of MTL-CEBPA in combination with standard of care treatments in pre-clinical models of liver cancer

Latest research from Rossi lab .@cityofhope on anti-inflammatory effects of MTL-CEBPA in mouse model of sepsis published in #MolecularTherapy

Load More...

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close